Pierre Hauser

This inventor holds 7 USPTO granted patents, plus 1 CIPO patent and 2 EPO patents. Top assignee: Smithkline Beecham Biologicals S.a.. Active years: 1998-2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pierre Hauser. Retrieved from https://idiyas.com/inventor/pierre-hauser

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7

% Patents Active = 71.4

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 3.0

ph-index = 5

Forward Citations = 165(Granted Patents)

Location History:

Belgium, BE (2000)
Chaumont-Gistoux, BE (1998 - 2005)

Company Filing History:

7 out of 75

Smithkline Beecham Biologicals S.a.

patents

Years Active: 1998-2005

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6893644 - Hepatitis vaccines containing 3-O-deacylated monophoshoryl lipid A (2005-05-17),

2. 6756040 - Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminum phosphate (2004-06-29),

3. 6620414 - Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A (2003-09-16),

4. 6488934 - Hepatitis B vaccine (2002-12-03),

5. 6013264 - Vaccine (2000-01-11),

6. 5972346 - Hepatitis B vaccine (1999-10-26),

7. 5776468 - Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A (1998-07-07),

Title: Pierre Hauser: Innovator in Vaccine Development

Introduction

Pierre Hauser is a notable inventor based in Chaumont-Gistoux, Belgium. He has made significant contributions to the field of vaccine development, holding a total of seven patents. His work focuses on innovative vaccine formulations aimed at preventing various infectious diseases.

Latest Patents

Among his latest patents, Hauser has developed a hepatitis vaccine that includes 3-O-deacylated monophosphoryl lipid A. This formulation is designed for the treatment or prophylaxis of hepatitis infections, particularly hepatitis B. The vaccine combines the hepatitis antigen with a suitable carrier, such as alum, enhancing its efficacy. Additionally, he has created a vaccine composition that comprises a polysaccharide conjugate antigen adsorbed onto aluminum phosphate. This invention targets the prevention of Haemophilus Influenzae Type B (Hib) infections and includes multivalent vaccines for the treatment of multiple disease states.

Career Highlights

Throughout his career, Pierre Hauser has worked with prominent companies in the pharmaceutical industry, including SmithKline Beecham Biologicals. His expertise in vaccine formulation has positioned him as a key player in the development of innovative medical solutions.

Collaborations

Hauser has collaborated with notable colleagues such as Pierre Voet and Pierre Desmons, contributing to advancements in vaccine technology.

Conclusion

Pierre Hauser's work in vaccine development has led to significant innovations that enhance public health. His contributions continue to impact the field of immunology and vaccine research.

Profile summary based on public USPTO records.